Evidence map›Paper›PMID 31127491›Full record

ArticleMolecular and cellular biochemistry2019

Empagliflozin restores the integrity of the endothelial glycocalyx in vitro.

Scott Cooper, Hwee Teoh, Marc Antoine Campeau, Subodh Verma, Richard L Leask

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06342141 (Empagliflozin for Reducing the Risk of No-Reflow Phenomenon in Patients Undergoing Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction), which is not on this map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06342141 phase2active not recruitingnot on this mapstarted 2024, after this paper: background citation

Empagliflozin for Reducing the Risk of No-Reflow Phenomenon in Patients Undergoing Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction

TypeinterventionalSponsorInstituto Nacional de Cardiologia Ignacio ChavezRan2024 to 2026Enrolled162ConditionsSTEMI, No-Reflow PhenomenonArmsEmpagliflozin 25 milgrams (Mg), Empagliflozin 10 Mg
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 67 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Leukocyte-endothelial interaction in CKD.Clinical kidney journal · 2023
    Review
  18. Review
  19. SGLT2 Inhibitors for Cardioprotection.Oman medical journal · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Scott CooperDepartment of Chemical Engineering, McGill University, 3610 University Street, Montréal, QC, H3A 2B2, Canada.ORCID http://orcid.org/0000-0001-9091-8269
Hwee TeohDivision of Endocrinology and Metabolism, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-1036-4767
Marc Antoine CampeauDepartment of Chemical Engineering, McGill University, 3610 University Street, Montréal, QC, H3A 2B2, Canada.ORCID http://orcid.org/0000-0001-7483-2094
Subodh VermaDivision of Cardiac Surgery, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-4018-8533
Richard L LeaskDepartment of Chemical Engineering, McGill University, 3610 University Street, Montréal, QC, H3A 2B2, Canada. richard.leask@mail.mcgill.ca.ORCID http://orcid.org/0000-0002-3649-5127
McGill University · CASt. Michael's Hospital · CAMontreal Heart Institute · CA

Funding

Canada Excellence Research Chairs, Government of Canada (CA) AtherosclerosisNatural Sciences and Engineering Research Council of Canada (CA) 261938-13
6 · The paper itself

Abstract

The antihyperglycemic agent empagliflozin not only improves glycemic control but has also been associated with clinically meaningful reductions in cardiovascular events. Studies have shown that empagliflozin significantly reduces cardiovascular death and heart failure-associated hospitalizations. Given that endothelial dysfunction is closely linked with the pathogenesis of atherosclerotic cardiovascular disease, we hypothesized that the cardiovascular benefits observed with empagliflozin may be a result of its positive impact on the health of the endothelial glycocalyx (GCX), a critical component for the endothelium homeostasis. Human abdominal aortic endothelial cells (HAAECs) were either statically cultured or subjected to a steady wall shear stress of 10 dyne/cm

Indexed as

Aorta, AbdominalBenzhydryl CompoundsCardiotonic AgentsCell Line, TumorEndothelial CellsEndothelium, VascularGlucosidesGlycocalyxHumansBenzhydryl CompoundsCardiotonic AgentsempagliflozinGlucosidesDiabetesEmpagliflozinEndotheliumGlycocalyx

Identifiers

PMID31127491
OpenAlexW2946777418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.